This review summarizes the most recent data on efficacy, risks, and benefits of novel biologic therapies in NSCLC focusing on EGFR, ALK, MET, ROS-1, and KRAS (Table 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.